Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Unity Biotechnology, Inc. (UBX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.5900+0.1900 (+7.92%)
At close: 01:00PM EST
2.5500 -0.04 (-1.54%)
After hours: 04:25PM EST
Advertisement

Unity Biotechnology, Inc.

285 East Grand Avenue
South San Francisco, CA 94080
United States
650 416 1192
https://unitybiotechnology.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees65

Key Executives

NameTitlePayExercisedYear Born
Dr. Anirvan Ghosh Ph.D.CEO & Director885.54kN/A1964
Dr. Nathaniel E. David A.B., Ph.D.Co-Founder & Exec. Director40kN/A1968
Ms. Lynne Marie SullivanCFO & Head of Corp. Devel.614.84kN/A1967
Dr. Jamie Dananberg M.D.Chief Medical Officer635.79kN/A1958
Dr. Jan M. van DeursenFounderN/AN/AN/A
Dr. Judith Campisi Ph.D.FounderN/AN/AN/A
Mr. Daohong Zhou M.D.FounderN/AN/AN/A
Mr. Nathan Guz Ph.D.VP of OperationsN/AN/AN/A
Mr. Alexander AzoyVP of Fin., Chief Accounting Officer, Controller & Principal Accounting OfficerN/AN/A1976
Dr. Przemyslaw Sapieha Ph.D.Chief Scientific AdvisorN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Corporate Governance

Unity Biotechnology, Inc.’s ISS Governance QualityScore as of November 1, 2022 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement